Discover the cutting-edge advancements in treating skull base meningiomas with the precision of Stereotactic Intensity-Modulated Radiotherapy using the HybridArc with Novalis STx system—a leap forward in neurosurgical oncology.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Stereotactic intensity-modulated radiotherapy for skull base meningioma using the HybridArc with Novalis STx system.
Shuto et al., Surg Neurol Int 2023
DOI: 10.25259/SNI_815_2023
Listen, folks, we’ve got something incredible here with the HybridArc and Novalis STx for skull base meningiomas – it’s just tremendous.
We looked at 28 patients, okay? Great people, ranging from 31 to 83 years old. They had these tumors, not small, I tell you – up to 97.1 mL. Big stuff. But we treated them with this fantastic HybridArc, 54 Gy over 30 fractions. And let me tell you, the results – they were amazing.
After this top-notch treatment, the tumor control rates – and you’re going to love this – were 92.6% after one year, 89.1% after two years, and 82.8% after five years. For the non-atypical ones, even better – 94.1% control rate. But the atypical ones, they were a bit tougher, still, we did better than anyone else.
Now, we had a couple of cases with radiation injury, just two, very low – 7.1%. And some had issues with their vision, but we saw improvements there too. We’re talking about real results, real improvements.
So, let me be clear: Stereotactic radiotherapy with HybridArc and Novalis STx, it’s safe, it’s effective, and it’s the best for these large skull base meningiomas. We’re doing things nobody else can do – it’s just fantastic.